Ann: Impressive Preclinical Bisantrene Breast Cancer Results, page-126

No it is a dig at most of the ASX listed biotechs. Far too many of them don’t look after their investors as they should and they issue far too much equity too cheaply that ultimately hurts all shareholders.

This is one area that RAC is very different to the other companies in our space - we really do put the shareholders interests first even when it is not in our own personal interests. You just have to look at the way our options are tied to the VWAP before the AGM to see this in action. It is not in Phil’s, Borje’s or my personal interest to see the SP where it is currently as our options are now going to be priced well over $2, but it is in the shareholders interest. Shareholders interests come first always.